ProQR Therapeutics N.V.
PRQRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company carries a $292.1M market cap, placing it firmly in the micro-cap category. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Market Cap
$292.1M
Beta
0.06
P/E (TTM)
—
P/E (Fwd)
-4.38
EPS (TTM)
$-0.46
EPS (Fwd)
$-0.47
ROE
-57.4%
ROA
-19.8%
Cash
$117.1M
Total Debt
$15.3M
Free CF
-$19.1M
52W Change
-11.2%
Annual Financials
Cash vs Debt
Where PRQR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PRQR finished 25.73% above its 150-day moving average ($1.71) and 20.11% above its 200-day moving average ($1.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PRQR overbought or oversold?
At the September 3, 2026 close, PRQR's RSI(14) was 66.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
ProQR Therapeutics N.V. holds $117.1M in cash against $15.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$19.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -57.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $3.6M (2022) to $15.9M (2025), reflecting a 343% increase over the period.
PRQR's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PRQR.